MIF deficiency does not alter glucose homeostasis or adipose tissue inflammatory cell infiltrates during diet-induced obesity

Obesity

Volumn 22, Issue 2, 2014, Pages 418-425

  Conine, Sarah J ^a   Cross, Janet V ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOSITY; ANIMALS; DIET, HIGH-FAT; DISEASE PROGRESSION; GLUCOSE INTOLERANCE; HYPERINSULINISM; INTRA-ABDOMINAL FAT; LIPID METABOLISM; LIVER; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; OBESITY; SUBCUTANEOUS FAT, ABDOMINAL; TIME FACTORS; WEIGHT GAIN;

EID: 84895907044     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20555     Document Type: Article

References (40)

1. Lumeng CN, Saltiel AR,. Inflammatory links between obesity and metabolic disease. J Clin Invest 2011; 121: 2111-2117.
2. Shoelson SE, Herrero L, Naaz A,. Obesity, inflammation, and insulin resistance. Gastroenterology 2007; 132: 2169-2180.
3. Kahn BB, Flier JS,. Obesity and insulin resistance. J Clin Invest 2000; 106: 473-481.
4. Hotamisligil GS, Shargill NS, Spiegelman BM,. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993; 259: 87-91.
5. Gregor MF, Hotamisligil GS,. Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-445.
6. Kanneganti TD, Dixit VD,. Immunological complications of obesity. Nat Immunol 2012; 13: 707-712.
7. Harford KA, Reynolds CM, McGillicuddy FC, Roche HM,. Fats, inflammation and insulin resistance: insights to the role of macrophage and T-cell accumulation in adipose tissue. Proc Nutr Soc 2011; 70: 408-417.
8. Chatzigeorgiou A, Karalis KP, Bornstein SR, Chavakis T,. Lymphocytes in obesity-related adipose tissue inflammation. Diabetologia 2012; 55: 2583-2592.
9. Donath MY, Shoelson SE,. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011; 11: 98-107.
10. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004; 89: 5043-5047.
11. Ghanim H, Aljada A, Hofmeyer D, Syed T, Mohanty P, Dandona P,. Circulating mononuclear cells in the obese are in a proinflammatory state. Circulation 2004; 110: 1564-1571.
12. Alvehus M, Burén J, Sjöström M, Goedecke J, Olsson T,. The human visceral fat depot has a unique inflammatory profile. Obesity (Silver Spring) 2010; 18: 879-883.
13. Verschuren L, Kooistra T, Bernhagen J, et al. MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease. Circ Res 2009; 105: 99-107.
14. Finucane OM, Reynolds CM, McGillicuddy FC, Roche HM,. Insights into the role of macrophage migration inhibitory factor in obesity and insulin resistance. Proc Nutr Soc 2012; 71: 622-633.
15. Stojanovic I, Saksida T, Stosic-Grujicic S,. Beta cell function: the role of macrophage migration inhibitory factor. Immunol Res 2012; 52: 81-88.
16. Waeber G, Calandra T, Roduit R, et al. Insulin secretion is regulated by the glucose-dependent production of islet beta cell macrophage migration inhibitory factor. Proc Natl Acad Sci U S A 1997; 94: 4782-4787.
17. Saksida T, Stosic-Grujicic S, Timotijevic G, Sandler S, Stojanovic I,. Macrophage migration inhibitory factor deficiency protects pancreatic islets from palmitic acid-induced apoptosis. Immunol Cell Biol 2012; 90: 688-698.
18. Serre-Beinier V, Toso C, Morel P, et al. Macrophage migration inhibitory factor deficiency leads to age-dependent impairment of glucose homeostasis in mice. J Endocrinol 2010; 206: 297-306.
19. Stosic-Grujicic S, Stojanovic I, Maksimovic-Ivanic D, et al. Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. J Cell Physiol 2008; 215: 665-675.
20. Sanchez-Zamora Y, Terrazas LI, Vilches-Flores A, et al. Macrophage migration inhibitory factor is a therapeutic target in treatment of non-insulin-dependent diabetes mellitus. FASEB J 2010; 24: 2583-2590.
21. Hoi AY, Iskander MN, Morand EF,. Macrophage migration inhibitory factor: a therapeutic target across inflammatory diseases. Inflamm Allergy Drug Targets 2007; 6: 183-190.
22. David JR,. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 1966; 56: 72-77.
23. Gregory JL, Morand EF, McKeown SJ, et al. Macrophage migration inhibitory factor induces macrophage recruitment via CC chemokine ligand 2. J Immunol 2006; 177: 8072-8079.
24. Simpson KD, Templeton DJ, Cross JV,. Macrophage migration inhibitory factor promotes tumor growth and metastasis by inducing myeloid-derived suppressor cells in the tumor microenvironment. J Immunol 2012; 189: 5533-5540.
25. Yaddanapudi K, Putty K, Rendon BE, et al. Control of tumor-associated macrophage alternative activation by macrophage migration inhibitory factor. J Immunol 2013; 190: 2984-2993.
26. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V,. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268.
27. Youn JI, Nagaraj S, Collazo M, Gabrilovich DI,. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791-5802.
28. Xia S, Sha H, Yang L, Ji Y, Ostrand-Rosenberg S, Qi L,. Gr-1+ CD11b+ myeloid-derived suppressor cells suppress inflammation and promote insulin sensitivity in obesity. J Biol Chem 2011; 286: 23591-23599.
29. Dietlin TA, Hofman FM, Lund BT, Gilmore W, Stohlman SA, van der Veen RC,. Mycobacteria-induced Gr-1+ subsets from distinct myeloid lineages have opposite effects on T cell expansion. J Leukoc Biol 2007; 81: 1205-1212.
30. Tu SP, Jin H, Shi JD, et al. Curcumin induces the differentiation of myeloid-derived suppressor cells and inhibits their interaction with cancer cells and related tumor growth. Cancer Prev Res (Phila) 2012; 5: 205-215.
31. Bozza M, Satoskar AR, Lin G, et al. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 1999; 189: 341-346.
32. Lansey MN, Walker NN, Hargett SR, Stevens JR, Keller SR,. Deletion of Rab GAP AS160 modifies glucose uptake and GLUT4 translocation in primary skeletal muscles and adipocytes and impairs glucose homeostasis. Am J Physiol Endocrinol Metab 2012; 303: E1273-E1286.
33. VelicËkovic NS, Djordjevic A, Vasiljevic ́ A, et al. Tissue-specific regulation of inflammation by macrophage migration inhibitory factor and glucocorticoids in fructose-fed Wistar rats. Br J Nutr 2012. DOI: http://dx.doi.org/10.1017/S0007114512005193.
34. Santos LL, Fan H, Hall P, et al. Macrophage migration inhibitory factor regulates neutrophil chemotactic responses in inflammatory arthritis in mice. Arthritis Rheum 2011; 63: 960-970.
35. O'Rourke RW,. Inflammation in obesity-related diseases. Surgery 2009; 145: 255-259.
36. Skurk T, Herder C, Kräft I, Müller-Scholze S, Hauner H, Kolb H,. Production and release of macrophage migration inhibitory factor from human adipocytes. Endocrinology 2005; 146: 1006-1011.
37. Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ,. The biology of white adipocyte proliferation. Obes Rev 2001; 2: 239-254.
38. Morris DL, Singer K, Lumeng CN,. Adipose tissue macrophages: phenotypic plasticity and diversity in lean and obese states. Curr Opin Clin Nutr Metab Care 2011; 14: 341-346.
39. Harper JM, Wilkinson JE, Miller RA,. Macrophage migration inhibitory factor-knockout mice are long lived and respond to caloric restriction. FASEB J 2010; 24: 2436-2442.
40. Fingerle-Rowson G, Petrenko O, Metz CN, et al. The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting. Proc Natl Acad Sci U S A 2003; 100: 9354-9359.